SCHEMBL22025929

SCHEMBL22025929

NNC(=O)Nc1cccc(O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
CYP1A2 P05177 1/20 0.61
KMT2A Q03164 4/20 0.58
MEN1 O00255 2/20 0.58
BAZ1A Q9NRL2 1/20 0.57
DDX3X O00571 1/20 0.53
TRPV1 Q8NER1 1/20 0.53
EPHX2 P34913 1/20 0.53
KDM4E B2RXH2 1/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
TP53 P04637 1/20 0.51
MAPK1 P28482 1/20 0.51
CNR1 P21554 1/20 0.51
MMP1 P03956 3/20 0.50
MMP2 P08253 3/20 0.50
MMP9 P14780 3/20 0.50
PYGL P06737 1/20 0.50
GRIK1 P39086 1/20 0.50
DYRK1A Q13627 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9400341 0.88 ALDH1A1 (0.70) ALDH1A1CYP1A2KMT2AMEN1BAZ1A
SCHEMBL7098404 0.82 TP53 (0.68) ALDH1A1CYP1A2KMT2AMEN1BAZ1A
SCHEMBL7097165 0.81 ALDH1A1 (0.67) ALDH1A1CYP1A2KMT2AMEN1BAZ1A
SCHEMBL9233836 0.81 DDX3X (0.81) ALDH1A1KMT2AMEN1DDX3XKDM4E
SCHEMBL3185695 0.80 KMT2A (0.66) ALDH1A1CYP1A2KMT2AMEN1BAZ1A
SCHEMBL29473480 0.79 ALDH1A1 (0.70) ALDH1A1CYP1A2KMT2AMEN1BAZ1A
SCHEMBL7514364 0.79 IDO1 (0.64) ALDH1A1KMT2AMEN1DDX3XTRPV1
SCHEMBL3076869 0.79 KMT2A (0.79) ALDH1A1CYP1A2KMT2AMEN1KDM4E
SCHEMBL5113893 0.79 RAB9A (0.65) ALDH1A1CYP1A2KMT2AMEN1NPC1
SCHEMBL9036479 0.79 HSD17B10 (0.65) ALDH1A1CYP1A2KMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243161-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2025-07-31 US disclosed
US-12269800-B2 Delivery of therapeutic alkaloid compounds SENSORIUM THERAPEUTICS, INC. (US) 2025-04-08 US disclosed
US-20250051277-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2025-02-13 US disclosed
US-20240246910-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2024-07-25 US disclosed
US-11999694-B2 Delivery of therapeutic alkaloid compounds SENSORIUM THERAPEUTICS, INC. (US) 2024-06-04 US disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 US disclosed
WO-2023076586-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
WO-2023076586-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
US-20210253518-A1 KINASE INHIBITOR NISSAN CHEMICAL CORPORATION (JP) 2021-08-19 US disclosed
US-20200165194-A1 ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME NISSAN CHEMICAL CORPORATION (JP) 2020-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051277-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT ALDH1A1 1109/4885CYP1A2 313/4885KMT2A 2128/4885
US-20250243161-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT ALDH1A1 1109/4885CYP1A2 313/4885KMT2A 2128/4885
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT ALDH1A1 1109/4885CYP1A2 313/4885KMT2A 2128/4885
US-20210253518-A1 KINASE INHIBITOR LATS2, LATS1, MAP3K6 ALDH1A1 3653/4885CYP1A2 4369/4885KMT2A 2351/4885
US-20240246910-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT ALDH1A1 1109/4885CYP1A2 313/4885KMT2A 2128/4885
US-20200165194-A1 ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME NEFM, FGF2, FGF1 ALDH1A1 1259/4885CYP1A2 3961/4885KMT2A 2745/4885
US-12269800-B2 Delivery of therapeutic alkaloid compounds PNMT, HNMT, NNMT ALDH1A1 1109/4885CYP1A2 313/4885KMT2A 2128/4885
US-11999694-B2 Delivery of therapeutic alkaloid compounds PNMT, HNMT, NNMT ALDH1A1 1109/4885CYP1A2 313/4885KMT2A 2128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.